Exploring the link between PLA levels and severity of sepsis cardiac insufficiency

Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency

This study is looking to see if higher levels of PLA in the blood are linked to how severe heart problems are in older patients with sepsis.

Quick facts

• Study type: Observational
• Enrollment: 30 (estimated)
• Ages: 50 Years to 90 Years
• Sex: All
• Sponsor: Dongzhimen Hospital, Beijing (other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06655389 on ClinicalTrials.gov

What this trial studies

This observational study investigates the relationship between circulating PLA levels and the severity of organ dysfunction in patients diagnosed with sepsis cardiac insufficiency. Conducted at Dongzhimen Hospital in Beijing, it aims to analyze how elevated PLA levels correlate with clinical outcomes in this patient population. The study will include hospitalized patients aged 50 to 90 years who meet specific criteria related to sepsis cardiac insufficiency and will also compare them to healthy controls. The findings could provide insights into potential evaluation and treatment strategies for this severe condition.

Who should consider this trial

Good fit: Ideal candidates for this study are hospitalized patients aged 50 to 90 years diagnosed with sepsis cardiac insufficiency.

Not a fit: Patients with conditions such as acute coronary syndrome or those with a history of long-term use of drugs affecting platelet function may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved assessment and management strategies for patients suffering from sepsis cardiac insufficiency.

How similar studies have performed: Previous studies have indicated a correlation between PLA levels and cardiac dysfunction in sepsis patients, suggesting that this approach has been explored with some success.

Eligibility criteria

Inclusion Criteria:

* Sepsis cardiac insufficiency group

  1. From April 2024 to December 2026, in the first ICU area of Dongzhimen Hospital, Beijing University of Chinese Medicine, Hospitalized patients in Zone II;
  2. consistent with the diagnosis of sepsis cardiac insufficiency;
  3. Age ≥ 50 and ≤ 90 years old;
  4. SOFA score≥ 2 points;
  5. Within 24 hours of the diagnosis of cardiac insufficiency in sepsis;
  6. The patient or his/her family members sign the informed consent form. Healthy subjects

  <!-- -->

  1. Aged ≥ 50 and ≤ 90 years old, permanent residents of Beijing community;
  2. Good health (blood routine, liver and kidney function, blood lipids, blood coagulation, no obvious abnormalities, no diagnosis cardiac insufficiency, acute coronary syndrome, old myocardial infarction, or cardiomyopathy);
  3. There is no history of long-term use of drugs that affect platelet function and coagulation function, and those who are willing to cooperate with the test Crowd;
  4. The subject himself signed the informed consent form.

Exclusion Criteria:

* 1\) Diagnosed with acute coronary syndrome, old myocardial infarction, and coronary heart disease revascularization of patients; (2) Cardiac insufficiency due to cardiomyopathy, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, hypothyroidic cardiomyopathy, etc.; (3) Due to heart knots Cardiac insufficiency caused by structural abnormalities, arrhythmias, cor pulmonale, nephroheart syndrome, etc.; (4) Impact Survival of severe primary diseases, including: uncontrolled malignant tumors that have metastasized in multiple places and cannot be resected, and blood disease, novel coronavirus infection and HIV, etc.; (5) Liver and kidney dysfunction with a single SOFA score of ≥3 points in liver or kidney handicappers; (6) Those who have been continuously using immunosuppressants or organ transplantation in the past 6 months; (7) 7 consecutive days prior to enrollment Those who have used corticosteroids, converted to methylprednisolone dose≥ 20mg/day; (8) Pregnant and lactating women; (9) Take or Injection of drugs that affect platelet function and coagulation function; (10) Those who have participated in other clinical trials within 30 days.

Where this trial is running

Beijing, Beijing Municipality

• DongzhimenH，Beijing — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Principal investigator: Nan Guo, Chief physician — DongzhimenH，Beijing
• Study coordinator: Yao Sheng Xiu

Conditions: Sepsis Cardiac Insufficiency, Sepsis cardiac insufficiency, PLA